AU2020228374A1 - Quinazolinone compounds - Google Patents

Quinazolinone compounds Download PDF

Info

Publication number
AU2020228374A1
AU2020228374A1 AU2020228374A AU2020228374A AU2020228374A1 AU 2020228374 A1 AU2020228374 A1 AU 2020228374A1 AU 2020228374 A AU2020228374 A AU 2020228374A AU 2020228374 A AU2020228374 A AU 2020228374A AU 2020228374 A1 AU2020228374 A1 AU 2020228374A1
Authority
AU
Australia
Prior art keywords
compound
hydrogen
alkyl
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020228374A
Other languages
English (en)
Inventor
Bingwei Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerepeut LLC
Original Assignee
Cerepeut LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerepeut LLC filed Critical Cerepeut LLC
Publication of AU2020228374A1 publication Critical patent/AU2020228374A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020228374A 2019-02-27 2020-02-26 Quinazolinone compounds Abandoned AU2020228374A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811471P 2019-02-27 2019-02-27
US62/811,471 2019-02-27
PCT/US2020/019942 WO2020176652A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Publications (1)

Publication Number Publication Date
AU2020228374A1 true AU2020228374A1 (en) 2021-09-23

Family

ID=72238692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020228374A Abandoned AU2020228374A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Country Status (9)

Country Link
US (1) US12454514B2 (https=)
EP (1) EP3930837A4 (https=)
JP (1) JP7597722B2 (https=)
KR (1) KR20210139279A (https=)
CN (1) CN113747943A (https=)
AU (1) AU2020228374A1 (https=)
CA (1) CA3131294A1 (https=)
IL (1) IL285805A (https=)
WO (1) WO2020176652A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
WO2013025508A1 (en) * 2011-08-12 2013-02-21 Southern Research Institute Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN111372921B (zh) * 2017-09-13 2023-12-01 赛勒佩特公司 小分子化合物
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20190307749A1 (en) * 2018-04-10 2019-10-10 Texas Tech University System Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease

Also Published As

Publication number Publication date
US20220162172A1 (en) 2022-05-26
US12454514B2 (en) 2025-10-28
WO2020176652A1 (en) 2020-09-03
EP3930837A4 (en) 2022-10-05
KR20210139279A (ko) 2021-11-22
IL285805A (en) 2021-10-31
JP2022523383A (ja) 2022-04-22
CN113747943A (zh) 2021-12-03
JP7597722B2 (ja) 2024-12-10
CA3131294A1 (en) 2020-09-03
EP3930837A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
TWI891621B (zh) 一種噠嗪類衍生物抑制劑、其製備方法和應用
JP5204486B2 (ja) シクロパミンアナログ及びその使用方法
JP2010526813A (ja) フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用
UA128528C2 (uk) Похідна піридопіримідину, спосіб її отримання та її медичне застосування
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CN112654622A (zh) 并环化合物、其制备方法及用途
KR20140147619A (ko) 신규한 칼콘 유도체 및 이의 용도
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
US12404251B2 (en) Small molecule compound
US12454514B2 (en) Quinazolinone compounds
AU2016205137A1 (en) Furoquinolinediones as inhibitors of TDP2
CN111247148B (zh) Wnt通路调节剂
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物
US9334280B2 (en) Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
CN110996930A (zh) 新型亚苄基丙酮衍生物及其用途
US11518744B2 (en) Benzamide compound and preparation method, use, and pharmaceutical composition thereof
KR20250024499A (ko) 벤조푸란 화합물 및 이를 포함하는 암 질환 및 암 전이의 예방 또는 치료용 약학적 조성물
CN111253390A (zh) 并环化合物、其制备方法及用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted